In the era of personalized medicine, molecular profiling has become essential for the treatment of patients with metastatic non-small cell lung carcinoma (NSCLC).  Next-generation sequencing (NGS), which can detect multiple alterations from a small amount of tissue, offers a solution. The Ion Torrent Oncomine Dx Target Test is the first targeted NGS-based in vitro diagnostic test for NSCLC, simultaneously delivering multiple biomarker results from one sample within four days, an aid in selecting which lung cancer patients may be eligible for treatment with specific FDA-approved drugs indicated for the treatment of NSCLC.

Oncomine Dx Target Test (US only)

The Oncomine Dx Targt Test is the first FDA-approved test that can detect multiple gene mutations for NSCLC in a single test from a single tissue sample. The Oncomine Dx  Target Test has been approved by the FDA as a companion diagnostic to aid in selecting which lung cancer patients may be eligible for treatment with specific FDA-approved drugs indicated for the treatment of NSCLC.

The Oncomine Dx Target Test will be available in July 2017 in the United States only. We are currently working on making it available in other countries. Details to be announced at a later date.